Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Dr. Schiller will discuss how their treatment approach would differ for a 74-year-old BPDCN patient with only well-controlled type 2 diabetes as a comorbidity and…
Amer Zeidan, MBBS, discusses the primary end point and subgroup analyses performed on the COMMANDS trial of luspatercept-amt for treating anemia in patients with myelodysplastic…
In separate, live virtual events, Kami J. Maddocks, MD, and Sairah Ahmed, MD, discussed the use of loncastuximab tesirine for a patient with later-line diffuse…
The FDA has approved the new drug application of tovorafenib for the treatment of pediatric low-grade glioma.
Yi-Bin Chen, MD, presents a patient case, detailing the symptomology and pathology of graft versus host disease, such as dry eyes, dry mouth, and difficulty…
Lova Sun, MD, MSCE, discusses resistance mechanisms against targeted agents for the treatment of thyroid cancer.
The FDA has approved the new drug application of tovorafenib for the treatment of pediatric low-grade glioma.
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
During a Case-Based Roundtable® event, Matthew A. Powell, MD, discussed the case of a patient with advanced endometrial cancer treated with lenvatinib plus pembrolizumab who experienced…
